Datapoint: Amgen Asks Supreme Court to Hear Repatha Case

Amgen is asking the U.S. Supreme Court to take up a previous ruling that invalidated two key patents for its PCSK9 drug, Repatha. A federal appeals court in June declined to hear the case. This is the latest chapter in a saga that dates back to 2014, when Amgen sued Sanofi and Regeneron to protect Repatha’s patents against a competing drug, Praluent, which ultimately delayed Praluent’s launch. For the treatment of atherosclerotic cardiovascular disease (ASCVD), Repatha holds covered or better status for 85% of all insured lives under the pharmacy benefit, compared to Praluent’s 76%.

SOURCE: MMIT Analytics, as of 12/1/21

0 Comments

AIS Health Staff

Related Posts

https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
January 20

Datapoint: Pfizer Scores Atopic Dermatitis Approval for Cibinqo

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
January 19

Datapoint: Centene Settles With New Hampshire in Medicaid Pharmacy Dispute

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
January 18

Datapoint: BCBSND Selected for North Dakota Medicaid Expansion

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today